BR112017001160A2 - [1,2,4]triazol[4,3-b]piridazinas para uso no tratamento de doenças proliferativas - Google Patents
[1,2,4]triazol[4,3-b]piridazinas para uso no tratamento de doenças proliferativasInfo
- Publication number
- BR112017001160A2 BR112017001160A2 BR112017001160A BR112017001160A BR112017001160A2 BR 112017001160 A2 BR112017001160 A2 BR 112017001160A2 BR 112017001160 A BR112017001160 A BR 112017001160A BR 112017001160 A BR112017001160 A BR 112017001160A BR 112017001160 A2 BR112017001160 A2 BR 112017001160A2
- Authority
- BR
- Brazil
- Prior art keywords
- pyridazine
- triazole
- treatment
- proliferative diseases
- formula
- Prior art date
Links
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002062 proliferating effect Effects 0.000 title 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 title 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 239000003139 biocide Substances 0.000 abstract 1
- 230000022534 cell killing Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
- C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
-
- E—FIXED CONSTRUCTIONS
- E21—EARTH OR ROCK DRILLING; MINING
- E21B—EARTH OR ROCK DRILLING; OBTAINING OIL, GAS, WATER, SOLUBLE OR MELTABLE MATERIALS OR A SLURRY OF MINERALS FROM WELLS
- E21B7/00—Special methods or apparatus for drilling
- E21B7/04—Directional drilling
- E21B7/06—Deflecting the direction of boreholes
-
- E—FIXED CONSTRUCTIONS
- E21—EARTH OR ROCK DRILLING; MINING
- E21B—EARTH OR ROCK DRILLING; OBTAINING OIL, GAS, WATER, SOLUBLE OR MELTABLE MATERIALS OR A SLURRY OF MINERALS FROM WELLS
- E21B7/00—Special methods or apparatus for drilling
- E21B7/04—Directional drilling
- E21B7/06—Deflecting the direction of boreholes
- E21B7/062—Deflecting the direction of boreholes the tool shaft rotating inside a non-rotating guide travelling with the shaft
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mining & Mineral Resources (AREA)
- Geology (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Fluid Mechanics (AREA)
- Geochemistry & Mineralogy (AREA)
- General Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Environmental & Geological Engineering (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
a invenção diz respeito a compostos da fórmula (i) (fórmula (i)) (i) ou seus sais farmaceuticamente aceitáveis, em que r1, r2 e n têm qualquer um dos significados aqui definidos anteriormente na descrição; processos para a sua preparação, composições farmacêuticas que os contêm e seu uso como agentes antiproliferativos e/ou que matam células.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462029676P | 2014-07-28 | 2014-07-28 | |
| PCT/GB2015/052143 WO2016016618A1 (en) | 2014-07-28 | 2015-07-24 | [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017001160A2 true BR112017001160A2 (pt) | 2017-11-14 |
Family
ID=53761420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017001160A BR112017001160A2 (pt) | 2014-07-28 | 2015-07-24 | [1,2,4]triazol[4,3-b]piridazinas para uso no tratamento de doenças proliferativas |
Country Status (36)
| Country | Link |
|---|---|
| US (5) | US9944650B2 (pt) |
| EP (1) | EP3174881B1 (pt) |
| JP (1) | JP6592503B2 (pt) |
| KR (1) | KR20170033427A (pt) |
| CN (1) | CN106536524B (pt) |
| AP (1) | AP2017009700A0 (pt) |
| AU (1) | AU2015295120B2 (pt) |
| BR (1) | BR112017001160A2 (pt) |
| CA (2) | CA2956421C (pt) |
| CL (1) | CL2017000223A1 (pt) |
| CO (1) | CO2017001918A2 (pt) |
| CY (1) | CY1120602T1 (pt) |
| DK (1) | DK3174881T3 (pt) |
| DO (1) | DOP2017000018A (pt) |
| EA (1) | EA032654B9 (pt) |
| ES (1) | ES2670444T3 (pt) |
| GT (1) | GT201700016A (pt) |
| HR (1) | HRP20180788T1 (pt) |
| HU (1) | HUE037571T2 (pt) |
| IL (1) | IL250104B (pt) |
| LT (1) | LT3174881T (pt) |
| MX (1) | MX2017001218A (pt) |
| MY (1) | MY187251A (pt) |
| NI (1) | NI201700006A (pt) |
| NO (2) | NO2719005T3 (pt) |
| PE (1) | PE20170527A1 (pt) |
| PH (1) | PH12017500159A1 (pt) |
| PL (1) | PL3174881T3 (pt) |
| PT (1) | PT3174881T (pt) |
| RS (1) | RS57242B1 (pt) |
| SG (1) | SG11201700419SA (pt) |
| SI (1) | SI3174881T1 (pt) |
| SV (1) | SV2017005368A (pt) |
| TN (1) | TN2017000018A1 (pt) |
| WO (1) | WO2016016618A1 (pt) |
| ZA (1) | ZA201701207B (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2719005T3 (pt) * | 2014-07-28 | 2018-01-20 | ||
| CN110317216A (zh) * | 2018-03-28 | 2019-10-11 | 首都医科大学 | 一种三唑并哒嗪类衍生物在医药领域的应用 |
| TWI816880B (zh) * | 2018-09-13 | 2023-10-01 | 大陸商恒翼生物醫藥（上海）股份有限公司 | 治療前列腺癌之組合療法 |
| JP2022552336A (ja) | 2019-10-14 | 2022-12-15 | アストラゼネカ・アクチエボラーグ | 造血器悪性腫瘍を治療するための併用療法 |
| EP4087572A1 (en) | 2020-01-09 | 2022-11-16 | AstraZeneca AB | Combination therapy for treating cancer |
| CN113143930B (zh) * | 2021-04-08 | 2023-05-30 | 深圳湾实验室 | 化合物在制备SARS-Cov-2 E蛋白抑制剂中的用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0525065D0 (en) * | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| WO2007065664A2 (en) | 2005-12-08 | 2007-06-14 | Novartis Ag | Pyrazolo[1,5-a]pyridine-3-carboxylic acids as ephb and vegfr2 kinase inhibitors |
| EP2235010A1 (en) | 2007-12-21 | 2010-10-06 | AstraZeneca AB | Bicyclic derivatives for use in the treatment of androgen receptor associated conditions |
| CN102388048B (zh) * | 2009-02-10 | 2014-07-30 | 阿斯利康(瑞典)有限公司 | 三唑并[4，3-b]哒嗪衍生物及其用于前列腺癌的用途 |
| JP2012526790A (ja) * | 2009-05-11 | 2012-11-01 | アストラゼネカ アクチボラグ | アンドロゲン受容体のリガンドとしての［１，２，４］トリアゾロ［４，３，ｂ］ピリダジン類 |
| HUE026421T2 (en) | 2009-11-05 | 2016-05-30 | Glaxosmithkline Llc | Benzodiazepine Bromine Domain Inhibitor |
| EP2721031B1 (en) * | 2011-06-17 | 2016-01-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| US9422290B2 (en) * | 2012-11-13 | 2016-08-23 | Boehringer Ingelheim International Gmbh | Triazolopyridazine |
| NO2719005T3 (pt) * | 2014-07-28 | 2018-01-20 |
-
2012
- 2012-05-17 NO NO12797323A patent/NO2719005T3/no unknown
-
2015
- 2015-07-24 PT PT157443086T patent/PT3174881T/pt unknown
- 2015-07-24 TN TN2017000018A patent/TN2017000018A1/en unknown
- 2015-07-24 MX MX2017001218A patent/MX2017001218A/es active IP Right Grant
- 2015-07-24 AP AP2017009700A patent/AP2017009700A0/en unknown
- 2015-07-24 CA CA2956421A patent/CA2956421C/en active Active
- 2015-07-24 DK DK15744308.6T patent/DK3174881T3/en active
- 2015-07-24 MY MYPI2017700325A patent/MY187251A/en unknown
- 2015-07-24 EA EA201790179A patent/EA032654B9/ru unknown
- 2015-07-24 HU HUE15744308A patent/HUE037571T2/hu unknown
- 2015-07-24 CA CA3185741A patent/CA3185741A1/en active Pending
- 2015-07-24 US US15/329,274 patent/US9944650B2/en active Active
- 2015-07-24 EP EP15744308.6A patent/EP3174881B1/en active Active
- 2015-07-24 CN CN201580039278.2A patent/CN106536524B/zh active Active
- 2015-07-24 NO NO15744308A patent/NO3174881T3/no unknown
- 2015-07-24 SI SI201530257T patent/SI3174881T1/en unknown
- 2015-07-24 SG SG11201700419SA patent/SG11201700419SA/en unknown
- 2015-07-24 AU AU2015295120A patent/AU2015295120B2/en not_active Ceased
- 2015-07-24 RS RS20180582A patent/RS57242B1/sr unknown
- 2015-07-24 ES ES15744308.6T patent/ES2670444T3/es active Active
- 2015-07-24 JP JP2017504710A patent/JP6592503B2/ja not_active Expired - Fee Related
- 2015-07-24 PE PE2017000095A patent/PE20170527A1/es unknown
- 2015-07-24 KR KR1020177005146A patent/KR20170033427A/ko not_active Application Discontinuation
- 2015-07-24 PL PL15744308T patent/PL3174881T3/pl unknown
- 2015-07-24 BR BR112017001160A patent/BR112017001160A2/pt active Search and Examination
- 2015-07-24 WO PCT/GB2015/052143 patent/WO2016016618A1/en active Application Filing
- 2015-07-24 LT LTEP15744308.6T patent/LT3174881T/lt unknown
-
2017
- 2017-01-15 IL IL250104A patent/IL250104B/en active IP Right Grant
- 2017-01-18 DO DO2017000018A patent/DOP2017000018A/es unknown
- 2017-01-26 PH PH12017500159A patent/PH12017500159A1/en unknown
- 2017-01-26 CL CL2017000223A patent/CL2017000223A1/es unknown
- 2017-01-27 NI NI201700006A patent/NI201700006A/es unknown
- 2017-01-27 GT GT201700016A patent/GT201700016A/es unknown
- 2017-01-27 SV SV2017005368A patent/SV2017005368A/es unknown
- 2017-02-17 ZA ZA2017/01207A patent/ZA201701207B/en unknown
- 2017-02-27 CO CONC2017/0001918A patent/CO2017001918A2/es unknown
-
2018
- 2018-04-11 US US15/950,443 patent/US10407432B2/en not_active Expired - Fee Related
- 2018-05-18 HR HRP20180788TT patent/HRP20180788T1/hr unknown
- 2018-05-18 CY CY181100512T patent/CY1120602T1/el unknown
-
2019
- 2019-08-01 US US16/528,738 patent/US10766905B2/en not_active Expired - Fee Related
-
2020
- 2020-07-16 US US16/930,911 patent/US11407755B2/en active Active
-
2022
- 2022-06-29 US US17/853,737 patent/US20230035133A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019012217A2 (pt) | compostos de amino-triazolopiridina e seu uso no tratamento de câncer | |
| BR112017001160A2 (pt) | [1,2,4]triazol[4,3-b]piridazinas para uso no tratamento de doenças proliferativas | |
| BR112019007393A2 (pt) | derivados 6,7,8,9-tetra-hidro-3h-pirazolo[4,3-f]isoquinolina úteis no tratamento de câncer | |
| BR112018077015A2 (pt) | derivados de ácido borônico e usos terapêuticos dos mesmos | |
| BR112018005497A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
| BR102018002152A8 (pt) | Compostos, composições farmacêuticas e seus usos como inibidores de hiv | |
| TR201901312T4 (tr) | Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri. | |
| BR112015029512A8 (pt) | derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas | |
| BR112017002811A2 (pt) | compostos de pirrolopirimidina usados como agonista de tlr7 | |
| BR112015029455A8 (pt) | compostos químicos, uso, métodos e composições para prevenção ou tratamento de câncer | |
| BR112018008397A2 (pt) | derivados de di-hidroimidazopirazinona úteis no tratamento do câncer | |
| BR112018000635A2 (pt) | compostos aza substituídos como inibidores irak-4 | |
| BR112016026291A2 (pt) | Derivados do ácido borônico e usos terapêuticos dos mesmos | |
| BR112018005904A2 (pt) | composto, e, método de prevenção e/ou tratamento do hiv. | |
| BR112018007772A2 (pt) | compostos de imidazo[4,5-c]quinolin-2-ona e seu uso no tratamento do câncer | |
| BR112018068532A2 (pt) | combinações de inibidores de lsd1 para o tratamento de malignidades hematológicas | |
| BR112018005870A2 (pt) | composto, e, método de prevenção e/ou tratamento do hiv. | |
| BR112015017331A2 (pt) | compostos químicos | |
| BR112015007366A2 (pt) | derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças | |
| BR112017016487A2 (pt) | 7-benzil-4- (2-metilbenzil) -2,4,6,7,8,9-hexahidroimidazo [1,2-a] pirrido [3,4-e] pirimidin-5 (1h) -ona, análogos desta, e sais do mesmo e métodos para sua utilização na terapia | |
| BR112013026397A2 (pt) | Compostos cromenona como inibidores de pi 3-cinase para o tratamento de câncer | |
| BR112016024421A2 (pt) | composição farmacêutica, cápsula e uso da composição farmacêutica | |
| BR112015019412A8 (pt) | inibidores de bace1, seus usos, e composição farmacêutica | |
| BR112017028456A2 (pt) | composto, e, método de prevenção e/ou tratamento de hiv | |
| BR112018070536A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B11D | Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time |